In line with this, TRIB2 could be used as a biomarker in melanoma since its expression strongly correlates specifically with both the presence and progression of melanocyte-derived malignancies [62] but not in samples from other tumour sources, including non-basal skin carcinoma [50]. Here, TRIB2 is linked to neoplasm.